Cure8 trial brief
Researchers tested whether adding metformin to standard mesalamine therapy changes disease activity in ulcerative colitis. If effective, metformin would be a low-cost, widely available adjunctive option worth further study.
Adults with ulcerative colitis, clinicians and researchers studying adjunctive drug therapies, and patients interested in clinical trials of repurposed drugs.
This is a completed phase 2 interventional clinical trial (NCT05553704) testing whether adding metformin 500 mg twice daily to standard mesalamine therapy (mesalamine 1 g three times daily) for 6 months changes disease activity in adults with ulcerative colitis.
The registered primary outcome is change in the Partial Mayo Score at 6 months, a noninvasive clinical index of UC activity.
The study planned enrollment was 60 adults (ages 18–75) and excluded people with diabetes, severe UC, recent or concurrent use of systemic steroids, immunosuppressants, or biologics, and those with significant liver or kidney dysfunction. The study was conducted at Mansoura University in Egypt and is listed as completed on ClinicalTrials.gov.
This record describes the trial design, eligibility, interventions, and primary outcome measure; it does not provide results or outcome data on whether metformin improved UC.
This is a ClinicalTrials.gov phase 2 trial record (completed) and does not include results in the provided text. The trial excluded diabetics and patients on steroids, immunosuppressants, or biologics; applicability is limited to the enrolled population.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...
